Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

NCT04486313 is registered in ClinicalTrials.gov with Romark Laboratories L.C. as lead sponsor.

NCT NCT04486313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04486313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Lead sponsor
Romark Laboratories L.C.
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2020
Completion date
February 8, 2021
Enrollment
935 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19